Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension

Obese patients are prone to arterial hypertension, require more antihypertensive medications, and have an increased risk of treatment-resistant arterial hypertension. Obesity-induced neurohumoral activation appears to be involved. The association between obesity and hypertension shows large inter-individual variability, likely through genetic mechanisms. Obesity affects overall cardiovascular and metabolic risk; yet, the relationship between obesity and cardiovascular risk is complex and not sufficiently addressed in clinical guidelines. The epidemiological observation that obesity may be protective in patients with established cardiovascular disease is difficult to translate into clinical experience and practice. Weight loss is often recommended as a means to lower blood pressure. However, current hypertension guidelines do not provide evidence-based guidance on how to institute weight loss. In fact, weight loss influences on blood pressure may be overestimated. Nevertheless, weight loss through bariatric surgery appears to decrease cardiovascular risk in severely obese patients. Eventually, most obese hypertensive patients will require antihypertensive medications. Data from large-scale studies with hard clinical endpoints on antihypertensive medications specifically addressing obese patients are lacking and the morbidity from the growing population of severely obese patients is poorly recognized or addressed. Because of their broad spectrum of beneficial effects, renin-angiotensin system inhibitors are considered to be the most appropriate drugs for antihypertensive treatment of obese patients. Most obese hypertensive patients require two or more antihypertensive drugs. Finally, how to combine weight loss strategies and antihypertensive treatment to achieve an optimal clinical outcome is unresolved.     

Doppler-derived mitral deceleration time: an early strong predictor of left ventricular remodeling after reperfused anterior acute myocardial infarction

BACKGROUND: The relation between remodeling and left ventricular (LV) diastolic function has not yet been fully investigated. The aim of this study was to determine whether early assessment of Doppler-derived mitral deceleration time (DT), a measure of LV compliance and filling, may predict progressive LV dilation after acute myocardial infarction (AMI). METHODS AND RESULTS: Fifty-one patients (aged 61+/-11 years; 6 women) with anterior AMI successfully treated with direct coronary angioplasty underwent 2-dimensional and Doppler echocardiographic examinations within 24 hours of admission, at days 3, 7, and 30 and 6 months after the index infarction. Mitral flow velocities were obtained from the apical 4-chamber view with pulsed Doppler. End-diastolic volume index (EDVI) and end-systolic volume index (ESVI) were calculated with the Simpson's rule algorithm. Patients were divided according to the DT duration assessed at day 3 in 2 groups: group 1 (n=33) with DT >130 ms and group 2 (n=18) with DT 相似文献   

鲨鱼软骨粉对小鼠移植性肿瘤的抑制作用与微血管的关系

观察鲨鱼软骨粉对小鼠移植性ＳＲＳ生长的影响与微血管密度的关系,方法肿瘤称重,切片用ｖＷＦ疫组化染色及微血管计算机扫描方法半定量。结果在已建立的小鼠ＳＲＳ实体瘤模型上应用口服鲨鱼软骨粉治疗,发现５４毫克／ｄ治疗１５ｄ后肿瘤重量及微血管密度较对照组明显减少。     

用流式细胞仪检测鲨鱼软骨粉提取物对大鼠微血管内皮细胞的作用

研究鲨鱼软骨粉提取物对大鼠肺微血管内皮细胞的影响,方法用流式细胞仪测定体外培养的肺微血管内皮细胞中细胞周期和细胞凋亡的变化。结果体外培养的微血管内皮细胞与鲨鱼软骨粉全成份、成份Ａ、成份Ｂ一起培养２４ｈ后经流式细胞仪检测发现,成份Ｂ使细胞周期Ｇ２－Ｍ期细胞明显减少,成份Ａ使凋亡细胞明显增加。